Isoforms of the transmembrane glycoprotein CD44, generated by alternative RNA splicing, have been correlated to tumor dissemination. For evaluation of the potential role of CD44 variant isoforms in non-Hodgkin's lymphoma (NHL), the presence of CD44 isoforms was analyzed in a large panel of reactive and neoplastic lymphoid tissues by immunohistochemical staining, as well as detection of CD44 variant RNAs by the revem transcriptase-polymerase chain reaction. Whereas the CD44 standard or hematopoietic isoform (CD44s1, devoid of the variant regions, was expressed in all leukocyte subpopulations, the variant isoforms (CD44v) showed a highly restricted pattern of expression, mainly ob-Y MEDIATING A VARETY of adhesive processes in cell-cell and cell-matrix interactions, the highly glycosylated cell surface protein, CD44, has been implicated in the migration and activation of leukocytes in immunosurveillance and inflammation, the formation of myeloid and lymphoid precursors in the bone marrow, and the development of lymphoid organs, as well as the interaction of cells with the extracellular microenvironment. This multitude of functions is probably mediated by different isoforms generated by alternative RNA splicing and by alterations in posttranslational m~dification.'-~ A total of 20 exons provide the coding information of the CD44 gene locus, but only nine of these are predominantly expressed as the so-called hematopoietic or standard form, CD44~.6*~ The other variably expressed exons, mainly encoding extracellular regions, contribute to the enormous variety of isoforms due to alternative splicing of the nuclear RNA generating multiple combinations of the so-called variant isoforms (CD44v).
Y MEDIATING A VARETY of adhesive processes in cell-cell and cell-matrix interactions, the highly glycosylated cell surface protein, CD44, has been implicated in the migration and activation of leukocytes in immunosurveillance and inflammation, the formation of myeloid and lymphoid precursors in the bone marrow, and the development of lymphoid organs, as well as the interaction of cells with the extracellular microenvironment. This multitude of functions is probably mediated by different isoforms generated by alternative RNA splicing and by alterations in posttranslational m~dification.'-~ A total of 20 exons provide the coding information of the CD44 gene locus, but only nine of these are predominantly expressed as the so-called hematopoietic or standard form, CD44~.6*~ The other variably expressed exons, mainly encoding extracellular regions, contribute to the enormous variety of isoforms due to alternative splicing of the nuclear RNA generating multiple combinations of the so-called variant isoforms (CD44v).
Based on data obtained with a spontaneous rat metastasis assay, CD44 variant isoforms containing exon 6v have been shown to be functionally involved in tumor di~semination.'.~ The identification of CD44v sequences in human tumor cell lines''." opened the route for an ever growing number of analyses of human tumor material indicating a potential involvement of CD44 variant isoforms also in human tumor disseminati~n.~>'~*'~ So far, an upregulation during tumor progression has been demonstrated for colon ~arcinoma,'~"~ for gastric car~inorna,'~.'' and for lymph~ma.'~-~' Correlations to clinical data are available in only one of these studies.Is
Non-Hodgkin's lymphoma (NHL) represents the neoplastic counterpart of leukocytes arrested at certain stages of activation and maturation. Thus, immunophenotypic and functional properties of normal lymphoid populations, such as the migratory capacity and regulated expression of adhesion molecules, are often retained by these Expression of CD44 in lymphoma and leukemia has been shown to parallel the expression pattern displayed during Tand B-cell ontogeny: expression of CD44 is strong in the earliest differentiation phases (represented by, eg, null-acute lymphocytic leukemia [ALL] , common-ALL, pre-T-ALL), is reduced in subsequent stages of development (represented by, eg, pre-B-ALL, B-ALL, T-ALL), and is increased again during more mature stages of lymphocyte ontogeny (represented by, eg, immunocytoma, hairy cell leukemia, myeloma, and peripheral T-cell NHL). Lymphoma from germinal centers like follicular B-lymphoma often shows a heterogeneous reactivity, thus apparently reflecting the weak CD44 expression in most germinal center In long-term bone marrow cultures, formation of myeloid or lymphoid cells was completely suppressed when CD44 monoclonal antibodies were applied at the initial stages of interaction between lymphocytes and stromal cells.26 Stimulation of lymphocytes results in the upregulation of CD44 variant isoforms, whereas resting lymphocytes do not express detectable levels of C D~~V . '~. '~ Moreover, the activation of lymphocytes can be blocked with antibodies directed at an epitope in CD44-6~.'~ Earlier studies on the expression of total CD44 in NHL showed a correlation between CD44 and an unfavorable clinical prognosis in comparison with patients with CD44 negative However, it was not possible to distinguish between CD44s and the different variant isoforms in these studies because the complexity of the CD44 isoforms was not known. When antibodies to the variant region became a~a i l a b l e '~.~~,~~ expression of CD44-6v was almost exclusively detected in high-grade malignant case^.'^*^' Evaluation of the exon compositions by reverse transcriptase-polymerase chain reaction (RT-PCR) also indicated an involvement of exon 6v in the dissemination of aggressive lymphoma."
Because clinical data on the correlation of CD44 variant isoforms and the prognosis of patients had not been presented, we were interested to find out whether in a cohort of 138 well-defined cases with an adequate clinical followup time we could establish CD44v as a new prognostic marker for NHL and give insight into the complexity and 
MATERIALS AND METHODS
Reactive tissues. Thymus samples were obtained from children undergoing cardiac surgery. Lymph nodes, tonsils, appendices, and skin were obtained after routine surgical procedures. Peyer's patches were collected from right hemicolectomy specimens that were resected for colon carcinoma. Spleen samples were obtained from three patients undergoing staging laparotomy because of hematologic neoplasia and from one patient in whom splenectomy was performed because of thrombopenia for therapeutic reasons. All specimens were determined pathologically to be nonmalignant.
Patients and clinical data. Tissue samples were analyzed from 181 patients who were referred for diagnosis and treatment to the Department of Internal Medicine, University Hospital Innsbruck from 1982 to 1993 (174 cases of B-NHL and 7 cases of T-NHL). NHL classification was performed according to the criteria of the Kiel classifi~ation~~ by applying conventional histologic and immunohistochemical criteria. In 138 of the 174 B-NHL patients, sufficient clinical data, as well as an adequate clinical follow-up time, were available. In these patients, expression of CD44 isoforms was compared with the clinical features age (median, 62 years; range, 5 to 90 years), sex (female, 55; male, 83), organ involvement (nodal v extranodal), the overall survival of patients, and the tumor stage according to the Ann Arbor classification system.'6 The staging procedure routinely included physical examination, chest x-rays, abdominaUpelvic/thoracic computed tomography, ultrasound examination of the abdomen, and bone marrow smears and biopsies. The distribution of low-and high-grade lymphoma (76 low/62 high grade) was the following according to the Ann Arbor staging: stage I (l/@, stage I1 (0/15), stage 111 (3/15), and stage IV (72/24). Patients were followed up for the median of 51 months (range, 4 to 123 months) or until death. Patients who had died from an unestablished cause or an intercurrent disease (n = 5 ) were excluded from analyses; 66 (48%) of 138 patients have died from lymphoma based on evidence from clinical course or autopsy. Thus, the 5-year survival rate was 58% (median survival, 70 months) in low-grade and 33% (median survival, 29 months) in high-grade lymphoma. An extranodal manifestation was detected in 33 of 62 high-grade lymphoma. Most of the lymphoma samples were collected before the start of chemotherapy. To evaluate possible influences on CD44v expression caused by the therapeutic regimen, comparative immunohistochemistry in treated versus untreated patients was performed, but different CD44v patterns have not been observed. In high-grade NHL prognostic factors as defined by the International NHL Prognostic Factor Project [ECOG performance status ( 5 1 v >2), extranodal involvement ( 5 1 v > I), age (560 yr v >60 yr), Ann Arbor stage (I, I1 v 111, IV), and serum LDH ( 5 1 n v > were evaluated and compared with CD44 expression.
Treatment was performed according to the histologic lymphoma subtype and the tumor stage. Low-grade lymphoma (chronic lymphocytic leukemia [CLL], immunocytoma) were managed similarly to the criteria mentioned recently.'8 Centroblastic-centrocytic lymphomas belonging to Ann Arbor stages I to 111 without bulky disease and few involved lymph node regions received radiation therapy combining the mantle and inverted Y-field, whereas patients of stage 111 with bulky disease or stage IV were treated with cyclophosphamide, vincristine, and prednisone (COP) or prednimustine and mitoxantrone (PmM) according to the schedule reported previously." In T-NHL and high-grade B-NHL (irnrnunoblastic, centroblastic, unclassified high-grade B-NHL, Ki-l NHL), treatment consisted of a doxorubicin-containing combination chemotherapy similarly to the described criteria,40 and Burkitt's NHL, as well as lymphoblastic NHL, were treated with intensified regimens for highly aggressive lymphoma.4' An autologous bone marrow transplant was performed in one patient with a Burkitt's lymphoma in first remission and an allogeneic transplant in a patient with a second relapse from a high-grade immunoblastic lymphoma.
Anti-CD44v antibodies. A panel of monoclonal antibodies (MoAbs) directed at products of variant exons 4v, 6v, and 9v, which have been obtained by immunizing Balb/c mice with a fusion protein corresponding to exons 3v to 1Ov of CD44, has been described re~ently.'~ Hybridoma supernatants of the following MoAbs were applied in immunohistochemistry: MoAb 11.10 directed at CD44-4v, 11.9 directed at CD44-6v, and I Immunostaining. Immunostaining of tissue sections was performed by using either a double-sandwich immunoperoxidase techn i q~e~~ or an alkaline phosphatase antialkaline phosphatase technique (APAAP).& Double staining was performed by consecutive application of APAAP and immunoperoxidase treatment. Bone marrow biopsies were stained applying an indirect immunoperoxidase method as described previ~usly?~ MoAbs of irrelevant specificities were used as first step negative controls. To confirm the specificity of the staining reaction, the reactivity of MoAb 11.9 was blocked by a synthetic peptide from exon CD44-6v (EETATQKEQWFG-NRWHEGYR) at a concentration of I O mg/mL, known to interfere with the binding of MoAb 1 1.9 to a CD44v fusion protein. 24 Staining intensity was scored semiquantitatively on a scale ofto +++ (-, negative; 2, faint, not clearly above background; +, weakly positive; + +, moderately positive; +++, strongly positive) using a cut-off point of 20% stained cells. Thus, lymphoma were termed positive when greater than 20% of the tumor cells showed a reactivity of +, ++, or +++ with the relevant MoAb. In accordance with published data,2y-" the staining intensity for CD44s turned out to represent a relevant prognostic factor. Therefore, an additional cutpoint was applied for CD44s evaluation (negative, faintly, or weakly positive v moderately or strongly positive. ie. -.
Preparation of RNA and cDNA/RT-PCR. Total cellular RNA was prepared using 5 pm frozen tissue sections or I O 5 cells, followed by treatment with acid phenollguanidinium isothio~yanate.~~-~' The CD44-specific PCR was performed essentially as described previo~sly.'~ Briefly, total RNA was isolated from one cryosection or pelleted cells followed by cDNA synthesis using random primers (Pharmacia, Freiburg, Germany) and mouse mammary leukemia virus reverse transcriptase (Promega, Zurich, Switzerland). cDNA amounts were equilibrated semiquantitatively for hypoxanthine phosphoribosyltransferase (HPRT) as a marker transcript to yield a PCR product of 0.84 kb in 15 pL reactions (primers: CCAAAGATG-GTCAAGGTCGC 5' sequence, positions 448 to 467 and CTGCTG-ACAAAGATTCACTGG 3' sequence, positions 1292 to 1272). The same amount of cDNA was taken for CD44-specific PCR amplification using primers homologous to the standard region directly flanking the variant sequences plus EcoRI recognition sequences . The PCR regime used was 95°C for 5 seconds, annealing 50°C (HPRT) or 60°C (CD44) for 15 seconds, extension 72°C for 1 minute over 31 cycles in an AMS Europe PCR cycler using AmpliTaq DNA polymerase (Hoffmann-La Roche, Basel, Switzerland). CD44 PCR products were aliquoted into five portions and separated on 1.2% agarose gels, blotted onto nylon membranes (Hybond N+; Amersham, Zurich, Switzerland), and subsequently hybridized individually with CD44 variant exon-specific probes, generated by PCR amplification using exon internal primers of each variant exon (Fig 1, small arrowheads) . The probes have been generated from cDNA (1 pgheaction) spanning the exons 2v to 1Ov; in addition, the cDNA from CD44s served as a source for determining the unspliced form, yielding a product of 67 bp. The following exon-specific primers were used for amplification of single variant exons to generate exon-specific probes: exon 2v ATAGGAATGATGTCACAGGTand5'CTGATAAGGAACGAT-TGACA). These exon-specific probes were labeled with "P-dCTP (Megaprime labeling kit; Amersham) and blots were hybridized and washed under stringent conditions (0.2 X SSC, 0.1% SDS, 65°C). Blots were exposed to Kodak X-AR films (Eastman-Kodak, Rochester, NY) at -70°C for 1 to 15 hours. A scheme of the CD44 gene CTITGATGAGCACTAGTGCT and 5' CAGCCATTTGTGTTGorganization indicating the exon nomenclature and the positions of the primers is given in Fig 1. Preparative RT-PCR and DNA sequence analysis. Four times the amount of cDNA as compared with the standard procedure was applied for transcript analysis from activated T cells (stimulated for 3 hours; Fig 2B) and from a high-grade malignant lymphoma (lane 5 in Fig 2D) . After performing the CD44-specific PCR, the reaction products were purified from low gelling agarose gels. Digestion with EcoRI showed suitable ends for subcloning because primers I and I1 (see Fig 1 and ") contain EcoRI restriction sites. After a colony screening for exon 6v-positive colonies, several colonies with different insert sizes have been sequenced.
T-cell activation.
The human T-cell clone DSH 11 (CD4-, CDS-) was obtained from Elisabetta Padovan (Basel Institute for Immunology, Basel, Switzerland) and stimulated with 1 pg/mL phytohemagglutinin (PHA). At various time points, samples of IO5 cells were withdrawn and resuspended in guanidinium isothiocyanate solution. Total cellular RNA and CD44-specific PCR reactions were prepared as described above for the standard procedure.
Statistical evaluation. The statistical significance between the presence of CD44 isoforms and the clinical parameters was determined by Fisher's exact test or the chi-square test depending on the number of cases. The probability of overall survival was computed according to the Kaplan-Meier method!* Statistical comparisons between curves were based on log-rank tests. Cox's regression analyses were performed for multivariate risk assessment. Relationship between prognostic factors was determined using Cox's proportional hazard model for covariate analysis of censored data?9 The significance test for stepwise addition of a variable to a model was based on the approximate chi-square distribution of twice the increment in log likelihood with entry of that variable into the model. The forward stepwise regression procedure was discontinued when the P value for a new variable entering was >.05. All analyses were performed by using the statistical package BMDP 90 (BDMP Statistical Software Inc, Los Angeles, CA)?'
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RESULTS
In a cohort of 181 NHL patients, with clinical records for 138, we performed immunohistochemical analyses for CD44, applying exon 3v-4v-, 6v-, and 9v-specific MoAb. To determine the composition of the expressed variant regions, RT-PCR data were evaluated using exon-specific probes. A scheme of the human CD44 molecule, indicating the epitope localizations of the MoAbs and the positions of the probes used for Southern hybridizations is given in Fig  1. Immunohistochemical analysis of CD44 isoforms in reactive tissues. CD44s showed a uniformly strong expression in most leukocyte and epithelial cell subpopulations ( Table  1 ). The only exception from this pronounced reactivity were some B cells within germinal centers, megakaryocytic cells in bone marrow, cortical thymocytes, and most subpopulations of thymic epithelium. In contrast, the expression of CD44 variant isoforms in reactive tissues was mainly restricted to epithelial cells. CD44-9v could be detected in epithelial cells of the mucosa-associated lymphoid organs (tonsil, Peyer's patch, and appendix), whereas the presence of CD44-3v, -4v, and -6v was restricted mainly to the epithelium of the tonsil. The thymus was characterized by a weak but homogeneous presence of several CD44 isoforms in Hassal's corpuscles and some scattered medullary epithelial cells. All leukocytes were constantly negative for CD44-3v, CD44-4v, CD44-6v, and CD44-9v. The only exception represented a fraction of CD44-9v-positive plasma cells and macrophages in reactive tissues.
Detection of CD44 isoforms in NHL by irnmunohistochemistry. CD44s was present in the majority of lymphoma (Table 2); differences in the intensity of expression were related to the histologic subtype, ie, low-grade lymphoma were often weakly positive for CD44s, whereas high-grade lymphoma were characterized by a strong reactivity for CD44s ( P < .0002) ( Table 3 ). The only significant exception within the group of high-grade NHL represented Burkitt's lymphoma, which often exhibited a weak expression of CD44s. The NHL subtypes were heterogeneous with respect to expression of variant isoforms. A substantial proportion of highgrade NHL showed presence of CD44-3v or -6v containing isoforms, whereas low-grade lymphoma were negative for both markers in nearly all cases (Table 2) .
MoAb25.32, recognizing all isoforms, detected CD44 not only on the lymphoma cells, but also on reactive lymphocytes (Fig 3A) . In contrast, the isoforms containing exons 3v, 6v, and 9v were exclusively present on the tumor cells, as demonstrated in a case of a high-grade Ki-l B-NHL (Fig  3B-D) . To verify the specificity of the reaction, a peptide representing the epitope for MoAbll.9 effectively blocked the staining (Fig 3E and F) . All but one (a Ki-l high-grade B-NHL) lymphoid tumors evaluated were negative for CD44-4v, whereas CD44-9v could be detected in some rare cases of high-grade lymphoma (Fig 3D) . In a small number of aggressive lymphoma, the presence of a few interspersed CD44-9v reactive macrophages was demonstrated, as verified by doublestaining (Fig 3G) . Some rare cases of aggressive lymphoma were characterized by the simultaneous expression of CD44-3v, -6v, and -9v containing isoforms ( Fig   3B, C, and D) . One case (see above) was additionally even positive for CD44-4v (not shown).
E.xpression of CD44 RNA transcripts in reactive lymphoid tissue, activated T lymphocytes, and lymphoma cells. To evaluate exon compositions in various lymphoid tissues, which is not possible by immunohistochemistry, RT-PCR analyses were performed, followed by Southern blotting, and detection with exon-specific probes (Figs 1 and 2A through  D) . Three reactive lymph nodes (Fig 2A, lanes 1 through  3) , which were obtained in the course of routine surgical procedures, were determined pathologically to be nonmalignant, whereas one lymph node (Fig 2A, lane 4) was infiltrated by metastasizing cells from a colon carcinoma. The expression patterns observed were different (Fig 2A) . Although expression of exon 3v, 6v, and 1Ov in the directly spliced version (ie, the variant exon flanked directly by the frameworklstandard sequence of CD44) was predominantly detectable in all of the lymph nodes, lymph node no. 4, in addition, showed expression of further variant exons. These additional transcripts were mainly compositions of exon 6v with 3v, 4v, 5v, or 7v, as well as 10v with 8v and 9v (Fig   2A, lane 4) . The reactive lymph nodes were almost devoid of further variant exons, except for a faint expression of 2v, 2v plus 3v and combinations of 1Ov with 8v and 9v in one of them (Fig 2A, lane l) .
Expression of CD44 isoforms in activated lymphocytes was analyzed after stimulation of a T-cell clone with PHA. Figure 2B demonstrates the alterations of CD44 isoform expression in a time course experiment. Exons 3v, 6v, and 1Ov contained within the framework sequence were expressed constantly without major variation on stimulation, as indicated by the size of the exon plus the size of the PCR product generated from the standard sequence (67 bp); ie, for exon 3v 193 bp, for exon 6v 196 bp, and for exon 1Ov 271 bp. However, larger variant regions became evident on stimulation for 3 to 6 hours. These combinations of several exons included mainly exons 6v in conjunction with exons 3v, 4v, 5v, 7v, and 8v, as presented in Fig 2B and confirmed by sequencing. Another set of exon combinations involved exons 2v, 3v plus 4v, as well as exons 8v plus 9v, which were also upregulated upon PHA treatment.
Analysis of CD44 isoform expression in 16 low-grade and 16 high-grade lymphoma cases each is shown in Fig 2C  and D . Human epidermis, which was included as a positive control (Fig 2C and D, lanes 17 ) expressed predominantly transcripts containing exons 3v-1Ov and 8v-10v."' All analyzed low-grade malignant NHL (Fig 2C, lanes l through  16 and another 15 cases of which the data are not presented) readily demonstrated expression of exon 3v-, 6v-, and 1 0~-containing isoforms in the directly spliced version, ie, the variant exon was contained within the standard CD44 sequence without further variant exons. Exons 8v and 9v were also more uniformly expressed, either singly or in combination with each other. The variant exons 2v, 4v, 5v, and 7v were not detected in all analyzed cases or were either weakly or moderately expressed, in combinations with another exon (2v + 3v; 4v + 5v; 7v + 8v) or singly within the framework sequence (Fig 2C) .
A rather different pattern of CD44 expression was observed in the high-grade NHL cases (Fig 2D, lanes I stages are impossible to differentiate on frozen sections.
16 and another 15 cases, data not shown). Exon 3v-, 6v, and l&-containing directly spliced isofoms were not as uniformly expressed as in the low-grade cases. Especially isoforms containing, in addition to exon 6v, further variant exons, like 4v, 5v, and 7v were of higher abundance. Also exon 1Ov was often associated with exon 9v. An exceptional combination of exons 3v-1Ov (lane 12 in Fig 2D) , resulting in a product of 1,081 bp was expressed in the tumor of a 23-year old woman with a polymorphic centroblastic lymphoma, who died 1 month after diagnosis. The patient showed a generalized dissemination, Ann Arbor stage N, and a disease refractory to treatment.
In another patient (lane 12 in Fig 2C) , whose tumor at the time of first diagnosis was classified as a low-grade NHL, then several months later developed a high-grade Ki-l B-NHL (shown in lane 3, Fig 2D) , the tissue sample taken initially exhibited supplementary to the directly spliced exon 6v pattern an additional band composed of exons 4v-5v-6v (lane 12 in Fig 2C) . A much more complex pattern, involving additional variant exons, was then detected in the more aggressive tumor at the time of relapse (lane 3 in Fig 2D) . Correlation of CD44 isofomz expression with the clinical outcome of patients. In accordance with the correlation to tumor grading (low-grade v high-grade B-NHL; Table 3 ), the overall survival of B-NHL patients was clearly influenced by the degree of CD44s reactivity, as well as by the presence of isoforms containing 3v or 6v (Table 3 and Table 3 ) and with the International Index as defined by the number of risk factors37 (P < .02 and < .04, respectively). Additionally, CD44s was correlated with a higher age of patients (P < .005) and CD44-3v with an elevated serum LDH (P < .05). Bone marrow involvement (12 positive cases of 16) seemed to be more often associated with strong CD44s expression than solely nodal involvement (1 3 reactivity; in lymphoma staining negatively for CD44-6v, positive cases of 28), but this correlation did not achieve the median survival time of patients was 65 months, as comstatistical significance ( P < .09). CD44s intensity of tumor pared with 9 months for CD44-6v expressing tumors (P < cells or CD44-6v expression were clearly associated with a . OOOl; Fig 4E) . However, these markers (CD44s, -3v, -6v) shorter overall survival of high-grade NHL patients (P < were correlated neither with Ann Arbor stage nor with age .05 and < .04, respectively; Fig 4B and F) , whereas CD44-or gender of patients (data not shown). Differences in the 3v did not achieve statistical significance in this subgroup clinical outcome of patients were not caused by different (Fig 4D) . CD44-6v was not correlated to any of the other treatment modalities, because the distribution of CD44 isoprognostic factors. forms within subgroups of patients was similar in terms of
In addition to the established prognostic value of CD44s treatment strategies applied (data not shown). Because of intensity ( Fig 4A and B and other ~tudies?~-~') this study the lack of CD44-4v and -9v isoform detection by immunoidentifies CD44-6v as an additional parameter for an adverse histochemistry, in nearly all cases, a correlation to clinical clinical outcome of patients; subgrouping those cases with parameters was not definable.
low CD44s expression into positive versus negative CD44-As the correlation between the clinical outcome of patients 6v reactivity, patients who are CD44s -, 2, + and CD44-and the presence of CD44 isoforms was mainly caused by 6v -, 2 clearly had a better prognosis as opposed to those their strong expression in aggressive lymphomas, this subwho are CD44s -, 2, + and CD44-6v +, + +, + + + (Fig   group was evaluated separately . Furthermore, the prognostic 4G). Similarly, CD44-6v presence also indicated a worse value of CD44 expression was compared with relevant risk prognosis in the group with strong expression of CD44s factors defined recently by the International NHL (+ +, + + +) (Fig 4G) . A group of patients with an extremely Overall survival
As CD44-4v and -9v were negative in the majority of cases, a correlation to clinical parameters could not be estimated. Abbreviation: NS, not significant; NR, not reached. CD44s intensity turned out to be a clinical significant factor. Therefore, negative or weak expression was compared with srong expression t For CD44-3v and -6v negative v positive cases were evaluated (-, ? v +, ++, +++L * lb. lymphoblastic NHL; cb, centroblastic NHL; ib, immunoblastic NHL; cb-cc, centroblastic-centrocytic NHL; cc, centrocytic NHL; ic, immunocytic NHL. § The group of high-grade NHL consisted of Ib-, Burkitt-, cb-and ib-NHL, whereas CLL, ic, cb-cc and cc were included in the group of lowgrade NHL.
11 In high-grade NHL risk factors were evaluated according to the International Prognostic
As the performance status (ECOG scale 5 1 v 22) and the number of extranodal sites ( 5 1 v > l ) were not correlated to CD44 expression, these data have not been included in the table.
Serum LDH had not been determined for one of the patients. Therefore, the number of cases evaluated in comparison with LDH, as well as the International Prognostic Index, is 61.
(-, 2 , + v ++, +++).
Risk groups were defined by the number of International Prognostic Index risk factors according to Shipp et SI?'
poor prognosis was defined by the simultaneous expression of CD44s, -3v, and -6v on tumor cells (all 7 patients died; median survival, 13 months).
To evaluate the relative importance and independence of the different risk groups as defined by the International NHL Lymphoma Prognostic Factors intensity of CD44s expression, as well as presence of CD44 variant isoforms, were compared in Cox's stepwise proportional hazard model. International Index risk groups, as well as W -~V , emerged as independent prognostic factors in aggressive B-NHL, but not expression of CD44s or CD44-3v (Table 4 and Fig 4H) .
DISCUSSION
Adhesive interactions play pivotal roles in processes elementary for the immune system such as lymphohemopoiesis and leukocyte a~tivation.~' One of the molecules involved is the transmembrane glycoprotein CD44.'"*'' Because lymphoproliferative disorders such as NHL represent frozen stages of leukocyte development, evaluation of CD44 as a prognostic marker for lymphoma dissemination has been carefully analyzed over several Most of the studies were published before the presence of CD44, existing in a multitude of isoforms, became evident. It had long been discussed how a single molecule of 90 kD such as CD44 can be involved in a variety of functions as diverse as lymphocyte extravasation, embryogenesis, tumor dissemination, immune surveillance, and inflammati~n.'.'~ Knowing the diversity of CD44 variant isoforms, it is tempting to speculate that specific isoforms display distinctive roles in the above mentioned processes. However, specific ligands for the variant regions are still waiting to be identified. So . . . far, only regions from the standard part of CD44 have been described to bind to extracellular matrix molecules, namely hyaluronic acid, collagen, fibronectin, laminin,3,4 and sulfated p r~t e o g l y c a n .~~ When MoAbs specific for the human variant region became available, a cohort of 12 low-grade and 24 high-grade malignant NHL was analyzed. In IO high-grade lymphomas (42%), exon 6v containing isoforms have been detected; the low-grade NHL were completely devoid of CD44-6v." This finding was also confirmed in a study of 24 high-and 26 low-grade NHL, which also pointed out the prevalence of 3v containing isoforms in the high-grade cases.2' Using RT-PCR to analyze the composition of variant exons in 11 large cell lymphoma, mainly expression of the directly spliced exon 6v containing isoform was evident.*' In sera of NHL patients, increased amounts of CD44s and CD44-6v were found, showing a correlation with treatment response."
Because data on the expression of CD44 variant isoforms have not been correlated with clinical parameters so far, we attempted to test the validity of CD44v as a prognostic marker for survival in a large cohort of NHL patients. In addition to the immunohistochemical screening for 3v, 4v, 6v, and 9v containing isoforms, we also determined the exon composition by a refined RT-PCR approach.
In accordance with published data,3".3' the presence of CD44, not distinguishing the isoforms, was a significant prognostic factor in NHL. More importantly, our study gives evidence that expression of exon 3v or 6v containing isoforms is associated with a more aggressive phenotype of lymphomas and an unfavorable prognosis for patients. In the subgroup of high-grade NHL, presence of CD44-6v isoforms turned out to represent an independent prognostic parameter when compared with the prognostic subgroups as defined by the International NHL Prognostic Factor Project Index.37 In contrast, CD44s intensity or presence of CD44-3v did not emerge as independent risk factors because of their close correlation with parameters of the International Index. The prognostic relevance of CD44-6v expression suggests its inclusion and evaluation in larger prospective clinical trials to identify distinct patient risk groups in aggressive NHL.
To explore the splicing pattern of the exon 6v containing isoforms, a series of RT-PCR analyses showed the presence of exon 6v associated with 7v, 8v, 9v, andlor with 2v, 3v, 4v, and 5v in high-grade NHL. Whereas in low-grade NHL, exon 6v was almost exclusively expressed as the directly spliced single exon composition, nearly all analyzed highgrade NHL exhibit various combinations of exon 6v with other variant exons (Fig 2C and D) . The expression of exon 6v alone embedded into the standard framework of CD44 seems to represent a constitutive capacity of leukocytes. This became evident when a T-cell clone was stimulated: whereas the single exon 6v form was permanently expressed (although its expression increased on stimulation), larger isoforms were expressed after 3 to 6 hours of stimulation (Fig 2B) . These isoforms contained, in addition to exon 6v, exons 2v, 3v, 7v, 8v, 9v, and 1Ov and, thus, resemble to a considerable degree the pattern of transcripts observed in most of the high-grade lymphoma (Fig 2D) . This finding is in contrast to data presented by Arch et a127 and Salles et a12" pointing out the presence of exon 6v alone in activated lymphocytes and high-grade malignant lymphoma, as determined by RT-PCR. However, the RT-PCR analysis by Koopman et ally gave evidence as well for larger isoforms containing exon 6v in high-grade lymphoma.
Exon 6v is not the only variant exon that is constitutively expressed in lymphocytes as a single exon in the standard framework; this also holds true for exons 3v and 1Ov (Fig  2A, B , and C). Although earlier studies suggested a major involvement of CD44 in the organ-specific homing of leukocytes,'" subsequent investigations gave evidence for a more general role of CD44 in leukocyte migration to sites of inflammation." Therefore, it is tempting to speculate that the isoforms CD44-3v, CD44-6v, and CD44-1Ov are mediating specific cellular interactions during migration, whereas CD44s is mainly involved in interactions of lymphocytes (and epithelial and mesenchymal cells) to extracellular matrix and basement membrane components, such as hyaluronic acid, collagen, fibronectin, and laminin.
The precise analysis of variant exon compositions is of great importance in evaluating subtle differences in CD44v expression. We have established a procedure to determine the exon composition in a semiquantitative way by RT-PCR, followed by Southern blotting. As an improvement to the previously published procedure,34 we are now using exonspecific probes to demonstrate each variant exon separately. By using optimized conditions and highly specific detection methods, we are able to perform as many as 50 (on the average) PCR reactions from one frozen tissue section of 5 pm. Thus, in addition to CD44v, several other prognostic markers may be analyzed from the same cDNA preparation. Another alternative approach to determine the CD44 exon composition described recently" is based on the usage of as much as IO PCR reactions with different primer combinations for one sample, followed by careful size analysis of the reaction products. Applying this method analysis of tumor tissue samples exceeding IO will not only be time consuming and troublesome for the PCR reactions but above all for the determination of the exon composition structures.
Comparing the results obtained by immunohistochemical staining (Fig 3) with those from the RT-PCR (Fig 2) we realize that, although transcripts containing exons 3v, 6v, and 9v are readily demonstrated by RT-PCR, we are unable to detect positive staining in the same samples (reactive lymphoid tissue and low-grade NHL) by immunohistochemical analysis. Straightforward explanations of the differences observed would be the sensitivities of the methods applied are highly different, or posttranslational regulations lead to highly altered protein levels. However, this argument does not explain why almost similar amounts of transcript in the high-grade lymphoma, as observed by RT-PCR, show a positive signal in the immunostaining. The conformation of the antigen and the accessibility of the epitope may be different in the different isoforms, ie, the single variant exon isoform versus the isoform composed of 6v accompanied by other variant exons. In addition, it may not be feasible to compare the amounts of CD44v transcripts between high-grade and low-grade lymphoma due to the completely different proliferation features. The high growth rate of the aggressive lymphoma cells, equilibrated to the amount of HPRT produced, which may also be increased, would not allow quantitative comparisons with the group of less proliferating lowgrade NHL. Comparisons within each group in relation to the amount of HPRT produced per group is a semiquantitative measurement. Comparing the data between the two groups allows the determination of qualitative differences. The expression of the CD44-6v containing larger transcripts is demonstrable only in the high-grade malignant lymphoma over the baseline of the single exon transcript, as also present in the low-grade lymphoma.
What is the function of the larger CD44 isoforms, particularly those including exon 6v? Because ligands, specific for the variant region have not been described so far, we can only draw conclusions based on similarities between activated lymphocytes and aggressive lymphoma. Both share adhesive, invading, and migratory properties which could, at least in part, be mediated by CD44-6v containing isoforms. Activated lymphocytes are characterized by the capability to invade nonlymphoid organs, which is accompanied by increased cell proliferation, secretion of cytokines, and alterations of their adhesive properties. The involvement of CD44-6v isoforms in these processes was demonstrated by inhibiting successfully the activation of B and T lymphocytes with anti-CD44-6v antibodies in vitro.27 Low-grade malignant lymphomas have retained most of the functions of their normal counterparts like a nondestructive growth pattern, the respect of privileged sites (eg, central nervous system), the responsiveness to immunoregulation, and an indolent clinical course.63 Low-grade NHL resemble more the nonactivated lymphocytes as they are mostly negative for CD44-6v by immunohistochemical analysis. In contrast, high-grade lymphomas exhibit an autonomous cell proliferation, a destructive growth, and display many similarities with nonlymphoid tumors, such as carcinoma. It is tempting to speculate that isoforms, including exon 6v, are involved in lymphoma progression, as these variants have been shown to confer metastatic potential to nonmetastasizing rat pancreas carcinoma cell Furthermore, correlations between tumor progression and 6v containing isoforms have also been demonstrated for several human tumor^.^."
What are the differences between activated lymphocytes and high-grade malignant lymphoma? Apart from variance in their life span and aggressiveness of growth, activated lymphocytes express larger CD44-6v containing isoforms only transiently, while high-grade lymphoma do so constitutively, like carcinoma cells. Thus, the continuous expression, as well as the composition of exon 6v adjacent to other variant exons, may change the binding properties of the expressing cells in recruiting new cellular andor extracellular partner molecule^.^^ Aggressive lymphoma cells resemble, to a considerable degree, activated lymphocytes and the analysis of the function of CD44 variant isoforms may give insights into the processes of organ specific invasion in inflammation and tumor progression.
